USA flag logo/image

An Official Website of the United States Government

Drug Target Discovery in Mast Cells by GECKO Technology

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
65911
Program Year/Program:
2003 / SBIR
Agency Tracking Number:
AI056636
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
ATHERSYS, INC.
3201 CARNEGIE AVE CLEVELAND, OH 44115-2634
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2003
Title: Drug Target Discovery in Mast Cells by GECKO Technology
Agency: HHS
Contract: 1R43AI056636-01
Award Amount: $99,800.00
 

Abstract:

DESCRIPTION (provided by applicant): The goal of the present research program is to utilize a genome-wide, high-throughput gene knock-out technology in combination with cellular assays to identify anti-inflammatory drug targets. This novel knockout technology, termed Genome-wide Cell-based Knockout technology or GECKO, is capable of inactivating expression of each transcriptionally active gene in cultured cells. Genome-wide GECKO libraries contain a relatively small number of clones, typically less than 1,000,000 clones, wherein each clone contains a different gene knockout, and collectively each transcriptionally active gene has been knocked out within the library. In this phase I research program, we will establish mast cell activation assays compatible with the GECKO technology, and create a genome-wide GECKO library for identification of genes whose function is necessary for mast cell degranulation. The specific aims of this phase I program, therefore, are 1) to develop robust high-throughput assays to enable screens for mast cell mutants with defective activation and degranulation responses.; and 2) to generate a phenotypically stable, genome-wide, GECKO library for use in identifying degranulation mutants in the chosen mast cell model. Success in this Phase I program will enable a full scale effort to identify genes that inhibit various mast cell functions involved in allergy, asthma, and anaphylaxis as well as in degenerative fibrosis and arthritis, and thereby identify new drug targets for the treatment of inflammatory diseases.

Principal Investigator:

Paul D. Jackson
2164319900
PDJACKSON@ATHERSYS.COM

Business Contact:


2164319900
Small Business Information at Submission:

ATHERSYS, INC.
ATHERSYS, INC. 3201 CARNEGIE AVE CLEVELAND, OH 44115

EIN/Tax ID: 341830213
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No